Topic: mergers and acquisitions
Astellas buys Universal Cells, Teva is affected by Celltrion's manufacturing problem, Korea rolls out a digital health initiative.
J&J's diabetes unit attracts Chinese buyers, Novartis and Biocon form a biosimilar deal, plus Keytruda-Lenvima combo gets a breakthrough tag.
Takeda buys up TiGenix; some foreign drugs may be approved in China in 2018; Asian firms circle Sanofi's European generics unit.
Allscripts is shelling out $100 million for head-to-head EHR Practice Fusion, adding 30,000 physician practices to its portfolio.
Legend teams with J&J on CAR-T project, Eisai and Biogen's Alzheimer's drug fails in early readout, Impax and Bora Pharma ink deal.
Japan’s JSR bought Crown Biosciences, Aurobindo and Dr. Reddy’s responded to Orchid Pharma report, Tessa raised $80 million.
Aurobindo and Dr. Reddy’s each responded to a report by the Economic Times that said both were front-runners to buy bankrupt Orchid Pharma.
JLABS lands first ex-North America site in Shanghai, Sanofi's Dengvaxia situation quickly worsens in the Philippines, Astellas buys DMD biotech.
Cardinal Health has agreed to sell its China business to Shanghai Pharma for $557 million in cash.